P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback